Thursday, February 23, 2023 4:18:55 PM
I know what the difference is between 13F and 13D, don't need to read your prior posts - 13Fs are for 5% passive owners, 13Ds are for 5% activists, and the latter have to report changes in holdings in 10 or less days - the former just have to report 45 days after a quarter ends. I stand by what I said - I've never seen such a discrepancy in 13F and combined 13D/F/G holdings before.
How closely did you read my post? I asked why NASDAQ.com was showing a -19M shr sale when no such thing occurred - how can they mistakenly report an SEC filing that never happened? Don't be condescending to me dude - I'm one of the very first people to have ever posted on this board and have owned the stock for longer than most here - there are still 12 yr longs like me out there, but like me they just quit reading this board over the last couple years because it was a waste of time. You I don't know from a hole in the wall - appears you just started posting here on 2/2/23.
I've also been taking V for longer than anyone on this board - and that's unfortunate - personal knowledge of how damn good this drug is led me to invest much more than I'd usually put in any single stock - not so much that a pps of $1.70 puts my retirement funds in danger, but enough shrs that if AMRN had reached it's potential it could have funded half my retirement goal.
Also, SEC reporting is an SEC filing. Nothing to do with NASDAQ
How closely did you read my post? I asked why NASDAQ.com was showing a -19M shr sale when no such thing occurred - how can they mistakenly report an SEC filing that never happened? Don't be condescending to me dude - I'm one of the very first people to have ever posted on this board and have owned the stock for longer than most here - there are still 12 yr longs like me out there, but like me they just quit reading this board over the last couple years because it was a waste of time. You I don't know from a hole in the wall - appears you just started posting here on 2/2/23.
I've also been taking V for longer than anyone on this board - and that's unfortunate - personal knowledge of how damn good this drug is led me to invest much more than I'd usually put in any single stock - not so much that a pps of $1.70 puts my retirement funds in danger, but enough shrs that if AMRN had reached it's potential it could have funded half my retirement goal.
The Thought Police: To censor and protect. Craig Bruce
Recent AMRN News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026 • GlobeNewswire Inc. • 02/11/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:06 AM
